GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (XTAE:ENLV) » Definitions » Issuance of Debt

Enlivex Therapeutics (XTAE:ENLV) Issuance of Debt : ₪0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Enlivex Therapeutics Issuance of Debt?

Enlivex Therapeutics's Issuance of Debt for the three months ended in Sep. 2024 was ₪0.00 Mil.

Enlivex Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was ₪0.00 Mil.


Enlivex Therapeutics Issuance of Debt Historical Data

The historical data trend for Enlivex Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Issuance of Debt Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enlivex Therapeutics Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Ness Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Headlines

From GuruFocus